c2 - subsequent entry biologics patient perspective - attara - salon e
DESCRIPTION
TRANSCRIPT
Subsequent Entry BiologicsPatient Perspective
Gail Attara, Chief Executive Officer
Gastrointestinal Society
Chair, Best Medicines Coalition
Biologics…
• More than 200 years in Canada
• vaccine for smallpox, 1796
• insulin, 1921
• blood and its components
• human growth hormone
• interferon
• monoclonal antibody technology (mAb)
• many more…
Complexity
• biologic medicines are not new, but…
• they have evolved into
very intricate medicines
that continue to drastically
improve health outcomes
for patients in a number of
serious disease areas
• patients need safety
assurance
Small Molecules
• most common medicines, including dietary
supplements
• created by compounding organic and/or
inorganic chemical substances, which we
typically take orally
• about 90% of medicines are small molecule
monoclonal antibody
aspirin
Large Molecules• structurally elaborate agents
• grown through a complex biologic process
using diverse human, animal, and/or
microorganism (e.g., bacteria, yeast) sources,
and are often produced using recombinant
DNA technology
• more than 1,000 process steps could be
necessary to assemble a complex medicine
and this information is proprietary
• we have to inject or infuse biologics, because
if we take them orally, we’ll digest them.
monoclonal antibody
aspirin
Copying – Not So Easy…
• innovator is not obligated to share its
manufacturing processes
• for small molecule medications, the
processes are relatively simple
• this is not true of biologics, where the
manufacturing process is integral to
creating the medication.
Patient Safety/Naming Issue
• strong regulatory need in Canada for distinguishable international non-proprietary names (INNs) between the innovator and SEB medications to ensure that real world usage data attaches to the applicable medicine
• need to protect physicians’ authority to prescribe the exact biologic or SEB that is right for each patient
Patient Concerns
• large molecule biosimilars/SEBs are
only similar and never bioequivalent
with innovator products
• biologics/SEBs must never have
interchangeability status
• one key can’t open every door
Patient Concerns• SEBs should go through the same
rigorous testing for safety & efficacy as
the innovator for each disease expected
to benefit from the new medicine
• it should not be as easy for SEBs to
expand indications to treat a condition as
it has been for small molecule generic
medications
Patient Engagement
we strongly support an
environment of patient
engagement in all stages of the
medication continuum for patient
safety
Patient Engagement
patients, as the end users
of these medications, have vital
knowledge about the disease
processes and the potential value
these medications could
add to their lives